Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.)

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

SEPTEMBER 15, 2021

More than 100 people in the US have been hospitalized in 2021 after using Delta-8 THC products, federal health regulators warned Tuesday. The FDA has received adverse event reports involving delta-8 THC-containing products. Of the 22 patients, 19 experienced adverse events after ingesting delta-8 THC-containing food products (e.g.,

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

AUGUST 12, 2021

Net loss for the six months ended 30 June 2021 was $30.2 Net loss for the six months ended 30 June 2021 was $30.2 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

TheAnswerPage

MAY 16, 2021

According to one study involving 96 cancer patients receiving supportive cancer care, the data support the safety and effectiveness of medical marijuana as a complementary option for improving pain control, appetite and quality of life for cancer patients.

Safety 52

Safety Data Patients Events 52

The Blunt Truth

JANUARY 15, 2021

Last Friday, the Food and Drug Administration released a report on CBD, stating that more real-world data (RWD) is needed in order to evaluate the safety of the product. Further bulletins as events warrant. Cautious optimism seems to be the current mood in the industry. fda on cbd. new jersey. That’s now been delayed.

Research and Development 94

Research and Development CBD Programs Banking 94

Cannabis Law Report

JUNE 1, 2021

TORONTO, June 01, 2021 (GLOBE NEWSWIRE) — via InvestorWire – RYAH Group, Inc. We are pleased to bring RYAH’s IoT device and integrated data solutions to the United Kingdom, providing a new level of session accuracy, patient feedback consistency, and data integrity to the clinical framework in plant-based medicine research.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

NOVEMBER 26, 2021

(NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2021. On September 30, 2021, Can-Fite had approximately $13.3 Fortified Balance Sheet.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

JUNE 16, 2021

This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol. Training will be provided within the research program for licensed practitioners to assess the safety of psychedelic medicines and to classify and report positive and adverse events.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

FEBRUARY 20, 2022

Sales are growing, with monthly record sales of $319 million in June 2021. For 2021, Canadian sales are projected to reach US$4 billion, and US$6.7 Domestic carriers are staying away from the industry because of the immaturity of the market, but also because of a lack of data integrity and the stigma around the product.

Edibles 118

Edibles Hydroponic Retail Cannabis 118

Cannabis Law Report

JUNE 7, 2021

1.526 were reduced as expected and consistent with other CDC-reported data on vaccine-induced antibody neutralization against these variants 1. The study showed neutralizing antibody titers against B.1.1.7 were not significantly impacted, while neutralizing antibody titers against P1 and B.1.526 Dr. James A.

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

JUNE 1, 2021

Canopy Growth Reports Fourth Quarter and Fiscal Year 2021 Financial Results. Achieves 37% revenue growth in FY 2021 with strong double-digit growth across both cannabis and other consumer products businesses. Fourth Quarter Fiscal 2021 Financial Summary. (in Fiscal Year 2021 Financial Summary. (in Net revenue. 2,800) bps.

Data 95

Data Vaping Supply Chain Business 95

Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. Food and Drug Administration (FDA) has granted orphan drug designation to ganaxolone in TSC. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

AUGUST 6, 2021

Adjusted EBITDA loss in Q1 2022 was $64 million , a $29 million narrower loss versus Q1 2021 driven by higher sales and lower operating expenses. Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC ) today announces its financial results for the first quarter fiscal 2022 ended June 30, 2021.

Vaping 105

Vaping Research and Development Data Business 105

Cannabis Law Report

JUNE 16, 2021

Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols. – June 16, 2021) – Entheon Biomedical Corp. Developing insights through genetic testing and data are a key part of that mission.” Vancouver, British Columbia–(Newsfile Corp.

Research and Development 105

Research and Development Data Conditions Events 105

Cannabis Law Report

AUGUST 27, 2021

per Common Share for a period of four years from the closing date of the Private Placement, expected on or about September 12, 2021. HempFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Research and Development 105

Research and Development Events Hemp Food 105

Cannabis Law Report

JANUARY 12, 2022

In accordance with FDA requirements, an independent panel of qualified experts reviewed HempFusion’s safety dossier on its hemp-derived CBD extract, which included safety and toxicology studies, the published results of these studies, and a comprehensive review of the scientific literature on CBD. ABOUT HEMPFUSION.

Retail 52

Retail CBD Extraction Research and Development 52

Cannabis Law Report

AUGUST 3, 2021

million in 2020, which now triples HempFusion’s historical proforma revenue to ~$12 million with significant expansion planned for 2021 and beyond, making it immediately accretive to the Company. Further, the Company announces that Ian deQueiroz has resigned as a director of the Company effective July 30, 2021.

Research and Development 105

Research and Development Topical Events Compliance 105

Cannabis Law Report

SEPTEMBER 23, 2021

The FDA and CDC each issued warning notices to the public regarding delta-8 THC products on September 14, 2021, many of which are marketed as hemp products (and include some non-obvious references to other novel cannabinoids that may have similar effects and marketing). Delta-8 THC has psychoactive and intoxicating effects. CDC Health Alert.

THC 52

THC Concentrates Pets DEA 52

SpeedWeed

APRIL 7, 2021

Production will ramp up throughout the rest of 2021.”. And it’s good news for anyone with safety concerns about bong-ripping motorists. Last year in New York City, Hound Labs partnered with Triple Ring Technologies to study super spreader events. . He said his company is focused on getting field use data from its THCBA devices.

THC 52

THC Research and Development Safety Data 52

Cannabis Law Report

AUGUST 25, 2021

(“Sagely Naturals”), (together the “Acquisitions”) for fiscal 2021 and 2022. With the completion of the Acquisitions and inclusion of the pre-closing fiscal 2021 revenues of Apothecanna and Sagely Naturals, HempFusion expects to generate revenues of between USD$12.5 million in revenue. million and $13.5 million and $13.5

Retail 111

Retail Supply Chain Research and Development Events 111

Cannabis Law Report

DECEMBER 9, 2021

The Financing is expected to close on December 10, 2021. Dr. Johnson recently reported his interim results at Microdose’s Psychedelic Medicine Business Event, from his current smoking cessation study, utilizing a single macro-dose of psilocybin. DENVER, Dec. DENVER, Dec. Advancements in IP and Drug Development.

Clinical Trials 52

Clinical Trials Research and Development Treatment Therapy 52

TheAnswerPage

JANUARY 11, 2022

As a result, state medical marijuana rules and regulations have focused on the demands of the public without putting significant emphasis on the scientific data or the ability of the medical community to support and care for medical marijuana patients. Nov 24 2021. Journal of Clinical Gynecology and Obstetrics, North Amer, 0 Nov 2021.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

FEBRUARY 2, 2022

As federal legalization edges closer to reality, we believe the United States government will likely increase its role in setting the quality, consistency, and safety standards for medical and recreational cannabis products. Agrify brings data, science, and technology to its customers for unparalleled control over cultivation and extraction.

Extraction 52

Extraction Pharmaceutical Hemp Cultivation 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To 3 Nature Aging | VOL 1 | July 2021 | p. For more information, visit www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JUNE 2, 2021

Aggregate testing results will be reported to the director of the summer camp via safeCircle’s integration with CLEARED4, the Company’s pooled surveillance testing program partner, through CLEARED4’s smartphone-based online health safety management and reporting solution. Testing will be conducted from mid-June through end-July.

Clinical Trials 82

Clinical Trials Therapy Research and Development Collective 82

Cannabis Law Report

NOVEMBER 10, 2021

as well as to support Good Laboratory Practices (GLP) toxicology, safety studies and preclinical efficacy studies. In October 2021, Virpax announced that a $1.87 Also, the NIH engaged Battelle to conduct Dose Range Finding Studies, with the first study in rats being completed on October 7 th , 2021. About Virpax Pharmaceuticals.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

NOVEMBER 5, 2021

Hayward, president and CEO of Applied DNA, stated, “Employers are looking for an easy, customizable, and frictionless solution to help them meet all aspects of these new workplace safety and regulatory challenges. ” “CLEARED4 and Applied DNA have been working with large employers to get ready for these anticipated mandates.

Compliance 52

Compliance Compliance Research and Development Therapy 52

Cannabis Law Report

APRIL 8, 2022

The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer. Rick Doblin, Ph.D., Source: [link].

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JUNE 1, 2021

Company remains on track for potential approval of Vicineum™ in the US in August 2021. During his career, Dr. McLin has supported the launch of six products at start-up and mid-size pharmaceutical companies, where he has identified innovative, data-driven opportunities to engage patients, prescribers, and payers.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

DECEMBER 14, 2021

These new vaporizer pens complete Columbia Care’s initial medical product portfolio, which includes tinctures, launched in April 2020, and its proprietary solid-fill powder capsules, launched in April 2021, that remain unique in the UK market. In early 2021, the Company was the first to launch a solid-fill medical cannabis capsule in the UK.

Extraction 52

Extraction Patients Medicine Tincture 52

Cannabis Law Report

JULY 28, 2021

– July 28, 2021) – PharmaDrug Inc. The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company. Toronto, Ontario–(Newsfile Corp.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

SpeedWeed

APRIL 21, 2021

However, all is not lost as there are some “warm-up bands” on stage that have or will be issuing licenses before the big licensing events in NY, NJ, VA, and NM. The state is expanding the program in 2021. Ed Keating is a co-founder of Cannabiz Media and oversees the company’s data research and government relations efforts.

Programs 52

Programs Dispensary Oil Cultivation 52

Cannabis Law Report

NOVEMBER 9, 2021

Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. About LineaRx, Inc.,

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52